Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hematopoietic Stem Cell Transplantation | 70 | 2024 | 5649 | 5.570 |
Why?
|
Killer Cells, Natural | 32 | 2024 | 2201 | 5.190 |
Why?
|
Graft vs Host Disease | 45 | 2024 | 3024 | 4.100 |
Why?
|
Cyclophosphamide | 30 | 2024 | 2218 | 3.990 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 10 | 2021 | 263 | 3.680 |
Why?
|
Leukemia, Myeloid, Acute | 33 | 2024 | 3599 | 3.350 |
Why?
|
Transplantation Conditioning | 27 | 2024 | 1588 | 2.790 |
Why?
|
Hematologic Neoplasms | 14 | 2024 | 1890 | 1.760 |
Why?
|
Interleukin-15 | 7 | 2024 | 183 | 1.710 |
Why?
|
Lymphocyte Depletion | 5 | 2020 | 602 | 1.600 |
Why?
|
Immunotherapy, Adoptive | 12 | 2024 | 1454 | 1.430 |
Why?
|
Immunologic Memory | 7 | 2024 | 1353 | 1.340 |
Why?
|
Myelodysplastic Syndromes | 12 | 2024 | 1392 | 1.330 |
Why?
|
HLA Antigens | 8 | 2021 | 1368 | 1.310 |
Why?
|
Transplantation, Homologous | 20 | 2024 | 4809 | 1.250 |
Why?
|
Cord Blood Stem Cell Transplantation | 5 | 2021 | 305 | 1.250 |
Why?
|
Leukemia | 5 | 2021 | 1519 | 1.070 |
Why?
|
Tissue Donors | 9 | 2022 | 2311 | 1.050 |
Why?
|
Bone Marrow Diseases | 2 | 2017 | 232 | 0.940 |
Why?
|
Histocompatibility | 5 | 2019 | 316 | 0.930 |
Why?
|
Cytokines | 7 | 2024 | 7338 | 0.920 |
Why?
|
Granulocyte Colony-Stimulating Factor | 4 | 2021 | 629 | 0.900 |
Why?
|
Receptors, IgG | 3 | 2015 | 559 | 0.840 |
Why?
|
Myeloablative Agonists | 4 | 2019 | 209 | 0.840 |
Why?
|
Opportunistic Infections | 4 | 2023 | 375 | 0.800 |
Why?
|
Cytomegalovirus Infections | 6 | 2023 | 831 | 0.780 |
Why?
|
Multiple Myeloma | 5 | 2024 | 5129 | 0.770 |
Why?
|
Lymphocyte Transfusion | 2 | 2020 | 232 | 0.710 |
Why?
|
Histocompatibility Antigens Class I | 2 | 2024 | 1355 | 0.630 |
Why?
|
Cytotoxicity, Immunologic | 7 | 2024 | 1351 | 0.630 |
Why?
|
Hematopoietic Stem Cell Mobilization | 3 | 2021 | 225 | 0.610 |
Why?
|
T-Lymphocytes | 12 | 2024 | 10171 | 0.580 |
Why?
|
Neoplasms | 10 | 2024 | 22032 | 0.570 |
Why?
|
Cytomegalovirus | 3 | 2021 | 755 | 0.560 |
Why?
|
Epitopes | 3 | 2020 | 2502 | 0.550 |
Why?
|
Sarcoma, Myeloid | 1 | 2017 | 51 | 0.550 |
Why?
|
Tongue Diseases | 1 | 2017 | 68 | 0.550 |
Why?
|
Salvage Therapy | 4 | 2021 | 1268 | 0.520 |
Why?
|
Interleukin-2 | 2 | 2022 | 1888 | 0.510 |
Why?
|
Azacitidine | 5 | 2024 | 334 | 0.510 |
Why?
|
Humans | 122 | 2024 | 758406 | 0.480 |
Why?
|
Lymphocyte Subsets | 1 | 2015 | 310 | 0.460 |
Why?
|
Tongue | 1 | 2017 | 404 | 0.450 |
Why?
|
Leukemia, Myeloid | 1 | 2016 | 695 | 0.430 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2017 | 617 | 0.430 |
Why?
|
Acetates | 1 | 2014 | 321 | 0.420 |
Why?
|
Serum Albumin | 1 | 2016 | 673 | 0.420 |
Why?
|
Disease-Free Survival | 12 | 2021 | 6821 | 0.420 |
Why?
|
Recurrence | 10 | 2024 | 8426 | 0.390 |
Why?
|
Aged | 45 | 2024 | 168218 | 0.390 |
Why?
|
Virus Activation | 1 | 2013 | 319 | 0.390 |
Why?
|
ADAM Proteins | 1 | 2013 | 238 | 0.380 |
Why?
|
Adult | 57 | 2024 | 219935 | 0.380 |
Why?
|
Hematologic Diseases | 1 | 2015 | 496 | 0.370 |
Why?
|
Lymphocyte Activation | 5 | 2022 | 5490 | 0.370 |
Why?
|
Middle Aged | 50 | 2024 | 219568 | 0.370 |
Why?
|
Siblings | 7 | 2021 | 824 | 0.360 |
Why?
|
ABO Blood-Group System | 1 | 2013 | 367 | 0.360 |
Why?
|
Young Adult | 28 | 2024 | 58808 | 0.360 |
Why?
|
Mesenchymal Stem Cell Transplantation | 1 | 2015 | 498 | 0.360 |
Why?
|
Immunophenotyping | 1 | 2015 | 1871 | 0.350 |
Why?
|
Retrospective Studies | 35 | 2024 | 80168 | 0.350 |
Why?
|
Histocompatibility Testing | 4 | 2020 | 717 | 0.350 |
Why?
|
Immunocompromised Host | 2 | 2017 | 856 | 0.350 |
Why?
|
Encephalitis, Herpes Simplex | 1 | 2009 | 65 | 0.320 |
Why?
|
Hepatic Veno-Occlusive Disease | 2 | 2022 | 221 | 0.320 |
Why?
|
Remission Induction | 4 | 2019 | 2388 | 0.320 |
Why?
|
Survival Rate | 11 | 2021 | 12721 | 0.310 |
Why?
|
GPI-Linked Proteins | 2 | 2024 | 468 | 0.300 |
Why?
|
Quinazolines | 1 | 2014 | 1360 | 0.300 |
Why?
|
Bone Marrow Cells | 1 | 2015 | 2414 | 0.290 |
Why?
|
Lymphoma | 1 | 2017 | 1896 | 0.290 |
Why?
|
Bone Marrow Transplantation | 5 | 2023 | 2693 | 0.290 |
Why?
|
Peptides | 1 | 2019 | 4341 | 0.290 |
Why?
|
Ovarian Neoplasms | 1 | 2024 | 4876 | 0.290 |
Why?
|
Immunotherapy | 6 | 2024 | 4641 | 0.280 |
Why?
|
Health Personnel | 1 | 2020 | 3312 | 0.280 |
Why?
|
Immunosuppressive Agents | 7 | 2021 | 4158 | 0.280 |
Why?
|
Proteins | 3 | 2018 | 6026 | 0.270 |
Why?
|
K562 Cells | 4 | 2024 | 639 | 0.270 |
Why?
|
Interferon-gamma | 3 | 2015 | 3156 | 0.260 |
Why?
|
Male | 44 | 2024 | 358747 | 0.260 |
Why?
|
Antimetabolites, Antineoplastic | 3 | 2021 | 638 | 0.250 |
Why?
|
Epstein-Barr Virus Infections | 2 | 2023 | 608 | 0.250 |
Why?
|
Xenograft Model Antitumor Assays | 4 | 2024 | 3574 | 0.250 |
Why?
|
Cardiomyopathies | 1 | 2017 | 1944 | 0.240 |
Why?
|
Female | 44 | 2024 | 390323 | 0.240 |
Why?
|
HLA-A2 Antigen | 2 | 2022 | 211 | 0.240 |
Why?
|
Cell Line, Tumor | 8 | 2024 | 16886 | 0.240 |
Why?
|
Virus Diseases | 3 | 2021 | 719 | 0.240 |
Why?
|
Registries | 2 | 2019 | 8175 | 0.230 |
Why?
|
Antiviral Agents | 2 | 2014 | 3056 | 0.230 |
Why?
|
Adolescent | 22 | 2024 | 87892 | 0.230 |
Why?
|
Liver Transplantation | 1 | 2016 | 2325 | 0.230 |
Why?
|
Survival Analysis | 6 | 2019 | 10112 | 0.210 |
Why?
|
Activated-Leukocyte Cell Adhesion Molecule | 1 | 2022 | 21 | 0.210 |
Why?
|
Physicians | 1 | 2020 | 4580 | 0.210 |
Why?
|
Adrenergic Agents | 1 | 2022 | 74 | 0.200 |
Why?
|
Acute Disease | 5 | 2021 | 7225 | 0.200 |
Why?
|
Graft Survival | 3 | 2018 | 3794 | 0.200 |
Why?
|
Antigens, CD34 | 1 | 2024 | 653 | 0.200 |
Why?
|
Haplotypes | 3 | 2017 | 2764 | 0.200 |
Why?
|
Antineoplastic Agents | 3 | 2024 | 13591 | 0.190 |
Why?
|
Drug Resistance, Neoplasm | 3 | 2021 | 5249 | 0.190 |
Why?
|
Herpesviridae | 1 | 2021 | 106 | 0.190 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2023 | 9273 | 0.180 |
Why?
|
Chimerism | 1 | 2021 | 155 | 0.180 |
Why?
|
Single-Chain Antibodies | 1 | 2020 | 111 | 0.170 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2021 | 1627 | 0.170 |
Why?
|
Heterocyclic Compounds | 1 | 2021 | 246 | 0.170 |
Why?
|
BK Virus | 1 | 2020 | 123 | 0.160 |
Why?
|
Adoptive Transfer | 3 | 2016 | 819 | 0.160 |
Why?
|
Bone Marrow | 3 | 2019 | 2909 | 0.160 |
Why?
|
Treatment Failure | 1 | 2024 | 2640 | 0.150 |
Why?
|
Graft vs Leukemia Effect | 2 | 2020 | 121 | 0.150 |
Why?
|
Blood Donors | 2 | 2019 | 343 | 0.150 |
Why?
|
Dermatitis | 1 | 2019 | 200 | 0.150 |
Why?
|
Natural Killer T-Cells | 1 | 2021 | 311 | 0.150 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2017 | 1547 | 0.150 |
Why?
|
Ustilaginales | 1 | 2017 | 1 | 0.150 |
Why?
|
Transplantation, Autologous | 2 | 2021 | 2114 | 0.140 |
Why?
|
CD8-Positive T-Lymphocytes | 3 | 2020 | 4549 | 0.140 |
Why?
|
Patient Care Management | 1 | 2020 | 302 | 0.140 |
Why?
|
Community-Acquired Infections | 1 | 2021 | 460 | 0.140 |
Why?
|
Genes, Neoplasm | 1 | 2019 | 370 | 0.140 |
Why?
|
Dermatomycoses | 1 | 2017 | 48 | 0.140 |
Why?
|
Sulfonamides | 2 | 2024 | 1973 | 0.140 |
Why?
|
Receptors, Natural Killer Cell | 1 | 2016 | 57 | 0.140 |
Why?
|
Fungemia | 1 | 2017 | 58 | 0.140 |
Why?
|
Viremia | 2 | 2016 | 706 | 0.140 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2021 | 8506 | 0.130 |
Why?
|
Recombinant Fusion Proteins | 4 | 2018 | 3733 | 0.130 |
Why?
|
Lymphoproliferative Disorders | 1 | 2020 | 533 | 0.130 |
Why?
|
Lymphoma, T-Cell | 1 | 2019 | 304 | 0.130 |
Why?
|
Nitriles | 1 | 2021 | 957 | 0.130 |
Why?
|
Antigens, Differentiation, T-Lymphocyte | 2 | 2022 | 899 | 0.130 |
Why?
|
Immunity, Innate | 4 | 2022 | 3047 | 0.130 |
Why?
|
Yeasts | 1 | 2017 | 279 | 0.130 |
Why?
|
Premedication | 1 | 2016 | 247 | 0.130 |
Why?
|
Gram-Negative Bacterial Infections | 1 | 2017 | 237 | 0.130 |
Why?
|
Janus Kinase 1 | 1 | 2015 | 107 | 0.130 |
Why?
|
Proportional Hazards Models | 3 | 2021 | 12440 | 0.130 |
Why?
|
Treatment Outcome | 8 | 2021 | 64378 | 0.120 |
Why?
|
Anemia, Aplastic | 1 | 2017 | 228 | 0.120 |
Why?
|
Gram-Positive Bacterial Infections | 1 | 2017 | 343 | 0.120 |
Why?
|
Mucositis | 1 | 2016 | 108 | 0.120 |
Why?
|
Interleukin-18 | 2 | 2014 | 250 | 0.120 |
Why?
|
Cytokine-Induced Killer Cells | 1 | 2014 | 6 | 0.120 |
Why?
|
Age Factors | 4 | 2024 | 18358 | 0.120 |
Why?
|
Neuroblastoma | 1 | 2022 | 1251 | 0.120 |
Why?
|
Heparin | 1 | 2021 | 1632 | 0.110 |
Why?
|
Mice | 8 | 2024 | 81101 | 0.110 |
Why?
|
Incidence | 9 | 2023 | 21272 | 0.110 |
Why?
|
Primary Myelofibrosis | 1 | 2015 | 208 | 0.110 |
Why?
|
Ligands | 2 | 2019 | 3258 | 0.110 |
Why?
|
Respiratory Tract Infections | 1 | 2021 | 1005 | 0.110 |
Why?
|
Interleukin-12 | 2 | 2014 | 583 | 0.110 |
Why?
|
Stem Cell Transplantation | 1 | 2022 | 1599 | 0.110 |
Why?
|
Isoantibodies | 1 | 2017 | 661 | 0.110 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily D | 1 | 2012 | 30 | 0.110 |
Why?
|
Receptors, Interleukin-12 | 1 | 2012 | 26 | 0.110 |
Why?
|
Single-Cell Analysis | 1 | 2024 | 2379 | 0.110 |
Why?
|
Receptors, Interleukin-18 | 1 | 2012 | 24 | 0.110 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily C | 1 | 2012 | 35 | 0.110 |
Why?
|
Piperidines | 1 | 2021 | 1639 | 0.110 |
Why?
|
L-Selectin | 1 | 2013 | 209 | 0.100 |
Why?
|
Heart Failure | 1 | 2017 | 11593 | 0.100 |
Why?
|
Necrosis | 1 | 2017 | 1604 | 0.100 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 1 | 2014 | 305 | 0.100 |
Why?
|
Janus Kinase 2 | 1 | 2015 | 537 | 0.100 |
Why?
|
Receptors, Interleukin-2 | 1 | 2014 | 562 | 0.100 |
Why?
|
Induced Pluripotent Stem Cells | 1 | 2024 | 1842 | 0.100 |
Why?
|
Exanthema | 1 | 2017 | 504 | 0.100 |
Why?
|
Adipocytes | 1 | 2019 | 1177 | 0.100 |
Why?
|
Antifungal Agents | 1 | 2017 | 749 | 0.100 |
Why?
|
Receptors, KIR | 2 | 2024 | 113 | 0.100 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2021 | 1402 | 0.100 |
Why?
|
Predictive Value of Tests | 2 | 2019 | 15225 | 0.100 |
Why?
|
Hodgkin Disease | 1 | 2019 | 1377 | 0.100 |
Why?
|
Netherlands | 1 | 2016 | 2212 | 0.100 |
Why?
|
Saccharomyces cerevisiae | 1 | 2022 | 2695 | 0.090 |
Why?
|
Pyrazoles | 1 | 2021 | 1988 | 0.090 |
Why?
|
Transplantation Immunology | 1 | 2013 | 532 | 0.090 |
Why?
|
Myeloproliferative Disorders | 1 | 2017 | 606 | 0.090 |
Why?
|
Acute Kidney Injury | 1 | 2023 | 1926 | 0.090 |
Why?
|
Propensity Score | 1 | 2018 | 1907 | 0.090 |
Why?
|
Cell Proliferation | 3 | 2016 | 10416 | 0.090 |
Why?
|
Syndrome | 1 | 2016 | 3262 | 0.090 |
Why?
|
Animals | 9 | 2024 | 167768 | 0.080 |
Why?
|
Mice, Inbred NOD | 3 | 2021 | 1825 | 0.080 |
Why?
|
Lectins, C-Type | 1 | 2012 | 585 | 0.080 |
Why?
|
Pyrimidines | 1 | 2021 | 3006 | 0.080 |
Why?
|
Lymphoma, B-Cell | 1 | 2015 | 935 | 0.080 |
Why?
|
Chronic Disease | 5 | 2024 | 9267 | 0.080 |
Why?
|
Bacterial Infections | 1 | 2016 | 1401 | 0.080 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2017 | 1704 | 0.080 |
Why?
|
Vidarabine | 2 | 2021 | 336 | 0.080 |
Why?
|
Flow Cytometry | 2 | 2023 | 5864 | 0.080 |
Why?
|
Antigens, CD | 2 | 2022 | 3997 | 0.070 |
Why?
|
Benzimidazoles | 1 | 2013 | 855 | 0.070 |
Why?
|
DNA Methylation | 1 | 2021 | 4373 | 0.070 |
Why?
|
Protein Transport | 1 | 2013 | 1963 | 0.070 |
Why?
|
Secondary Prevention | 1 | 2013 | 1474 | 0.070 |
Why?
|
Neutrophils | 1 | 2020 | 3765 | 0.070 |
Why?
|
Coculture Techniques | 2 | 2023 | 1339 | 0.070 |
Why?
|
Herpesvirus 4, Human | 2 | 2023 | 1075 | 0.070 |
Why?
|
Donor Selection | 2 | 2019 | 227 | 0.070 |
Why?
|
Interleukin-6 | 1 | 2016 | 3208 | 0.070 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2016 | 2912 | 0.070 |
Why?
|
Macrophages | 1 | 2021 | 5737 | 0.070 |
Why?
|
Nuclear Proteins | 1 | 2020 | 5786 | 0.060 |
Why?
|
Simplexvirus | 1 | 2009 | 803 | 0.060 |
Why?
|
Membrane Proteins | 1 | 2022 | 7843 | 0.060 |
Why?
|
Risk | 2 | 2016 | 9599 | 0.060 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 4567 | 0.060 |
Why?
|
Cytarabine | 2 | 2017 | 696 | 0.060 |
Why?
|
Mutation | 2 | 2022 | 29915 | 0.060 |
Why?
|
Protein Processing, Post-Translational | 1 | 2013 | 1972 | 0.060 |
Why?
|
Kaplan-Meier Estimate | 3 | 2021 | 6493 | 0.060 |
Why?
|
Echocardiography | 1 | 2017 | 4962 | 0.060 |
Why?
|
Peptide Fragments | 1 | 2017 | 5098 | 0.060 |
Why?
|
Time Factors | 3 | 2017 | 39872 | 0.060 |
Why?
|
Cell Membrane | 1 | 2013 | 3680 | 0.050 |
Why?
|
Risk Factors | 5 | 2020 | 73809 | 0.050 |
Why?
|
Cells, Cultured | 3 | 2014 | 18940 | 0.050 |
Why?
|
Stroke Volume | 1 | 2017 | 5460 | 0.050 |
Why?
|
Follow-Up Studies | 4 | 2021 | 39059 | 0.050 |
Why?
|
B-Cell Maturation Antigen | 1 | 2024 | 148 | 0.050 |
Why?
|
Neoplasm, Residual | 2 | 2018 | 1007 | 0.050 |
Why?
|
Fetal Proteins | 1 | 2022 | 97 | 0.050 |
Why?
|
Enzyme Inhibitors | 1 | 2013 | 3709 | 0.050 |
Why?
|
Comorbidity | 1 | 2017 | 10495 | 0.050 |
Why?
|
Cytotoxicity Tests, Immunologic | 1 | 2021 | 321 | 0.050 |
Why?
|
Cohort Studies | 2 | 2015 | 41256 | 0.050 |
Why?
|
Cell Adhesion Molecules, Neuronal | 1 | 2022 | 263 | 0.050 |
Why?
|
Busulfan | 1 | 2021 | 258 | 0.050 |
Why?
|
Polydeoxyribonucleotides | 1 | 2022 | 136 | 0.050 |
Why?
|
Immunologic Factors | 2 | 2022 | 1585 | 0.050 |
Why?
|
Sensitivity and Specificity | 1 | 2016 | 14641 | 0.050 |
Why?
|
Mice, SCID | 2 | 2017 | 2626 | 0.040 |
Why?
|
Drug Therapy, Combination | 2 | 2021 | 6293 | 0.040 |
Why?
|
Ohio | 1 | 2021 | 321 | 0.040 |
Why?
|
Multivariate Analysis | 1 | 2013 | 12096 | 0.040 |
Why?
|
Benzylamines | 1 | 2021 | 247 | 0.040 |
Why?
|
Tacrolimus | 1 | 2023 | 733 | 0.040 |
Why?
|
Fever | 2 | 2017 | 1617 | 0.040 |
Why?
|
Chemokine CXCL12 | 1 | 2021 | 454 | 0.040 |
Why?
|
Consensus | 2 | 2019 | 3099 | 0.040 |
Why?
|
Child, Preschool | 3 | 2021 | 42062 | 0.040 |
Why?
|
Protein Kinase Inhibitors | 1 | 2015 | 5629 | 0.040 |
Why?
|
Gene Expression Regulation | 2 | 2014 | 11892 | 0.040 |
Why?
|
Child | 5 | 2021 | 79818 | 0.040 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2022 | 886 | 0.040 |
Why?
|
Antigen Presentation | 1 | 2023 | 1254 | 0.040 |
Why?
|
Missouri | 1 | 2017 | 114 | 0.040 |
Why?
|
Reproducibility of Results | 1 | 2016 | 20055 | 0.040 |
Why?
|
Cladribine | 1 | 2017 | 34 | 0.040 |
Why?
|
MicroRNAs | 1 | 2013 | 3783 | 0.040 |
Why?
|
Trichosporon | 1 | 2017 | 9 | 0.040 |
Why?
|
Filgrastim | 1 | 2017 | 132 | 0.040 |
Why?
|
Mitoxantrone | 1 | 2017 | 148 | 0.040 |
Why?
|
Idarubicin | 1 | 2017 | 59 | 0.040 |
Why?
|
Aged, 80 and over | 5 | 2021 | 58683 | 0.040 |
Why?
|
Cryptococcus | 1 | 2017 | 28 | 0.040 |
Why?
|
Signal Transduction | 3 | 2017 | 23342 | 0.040 |
Why?
|
Echinocandins | 1 | 2017 | 51 | 0.040 |
Why?
|
Saccharomyces | 1 | 2017 | 63 | 0.040 |
Why?
|
Lipopeptides | 1 | 2017 | 72 | 0.030 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2024 | 1765 | 0.030 |
Why?
|
Nuclear Family | 1 | 2018 | 313 | 0.030 |
Why?
|
Chromatin Assembly and Disassembly | 1 | 2021 | 633 | 0.030 |
Why?
|
Amphotericin B | 1 | 2017 | 142 | 0.030 |
Why?
|
Cell Degranulation | 1 | 2017 | 276 | 0.030 |
Why?
|
Receptors, CXCR4 | 1 | 2021 | 727 | 0.030 |
Why?
|
Living Donors | 1 | 2021 | 638 | 0.030 |
Why?
|
Cryopreservation | 1 | 2021 | 717 | 0.030 |
Why?
|
Graft Rejection | 2 | 2021 | 4426 | 0.030 |
Why?
|
Steroids | 1 | 2021 | 926 | 0.030 |
Why?
|
5-Methylcytosine | 1 | 2016 | 146 | 0.030 |
Why?
|
Leukocytes, Mononuclear | 1 | 2023 | 1826 | 0.030 |
Why?
|
Etoposide | 1 | 2017 | 630 | 0.030 |
Why?
|
Adenine | 1 | 2021 | 975 | 0.030 |
Why?
|
Phenotype | 2 | 2024 | 16534 | 0.030 |
Why?
|
Perforin | 1 | 2015 | 167 | 0.030 |
Why?
|
Drug Evaluation | 1 | 2016 | 638 | 0.030 |
Why?
|
Drug Resistance | 1 | 2021 | 1593 | 0.030 |
Why?
|
Isocitrate Dehydrogenase | 1 | 2021 | 929 | 0.030 |
Why?
|
Antibody-Dependent Cell Cytotoxicity | 1 | 2015 | 303 | 0.030 |
Why?
|
Gastrointestinal Tract | 1 | 2020 | 829 | 0.030 |
Why?
|
Mycoses | 1 | 2017 | 386 | 0.030 |
Why?
|
Granzymes | 1 | 2015 | 276 | 0.030 |
Why?
|
Electroencephalography | 1 | 2009 | 6187 | 0.030 |
Why?
|
Neoplasm Transplantation | 1 | 2017 | 2013 | 0.030 |
Why?
|
Specific Pathogen-Free Organisms | 1 | 2013 | 219 | 0.030 |
Why?
|
Fetal Blood | 1 | 2020 | 1343 | 0.030 |
Why?
|
Cell Lineage | 1 | 2022 | 2533 | 0.030 |
Why?
|
STAT5 Transcription Factor | 1 | 2014 | 263 | 0.030 |
Why?
|
Integrins | 1 | 2017 | 836 | 0.030 |
Why?
|
Calcineurin | 1 | 2013 | 229 | 0.030 |
Why?
|
Antigens, Neoplasm | 1 | 2020 | 1997 | 0.030 |
Why?
|
Neutropenia | 1 | 2017 | 884 | 0.030 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2017 | 685 | 0.020 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2021 | 2825 | 0.020 |
Why?
|
Lymphocytes | 1 | 2019 | 2610 | 0.020 |
Why?
|
Adrenal Cortex Hormones | 1 | 2020 | 1870 | 0.020 |
Why?
|
Drug Synergism | 1 | 2015 | 1745 | 0.020 |
Why?
|
Models, Immunological | 1 | 2013 | 513 | 0.020 |
Why?
|
Cardiovascular Diseases | 1 | 2017 | 15399 | 0.020 |
Why?
|
Infant | 1 | 2013 | 36055 | 0.020 |
Why?
|
Transduction, Genetic | 1 | 2013 | 896 | 0.020 |
Why?
|
Lentivirus | 1 | 2013 | 503 | 0.020 |
Why?
|
Prospective Studies | 3 | 2021 | 54137 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2023 | 3840 | 0.020 |
Why?
|
Vaccination | 1 | 2022 | 3355 | 0.020 |
Why?
|
Genes, Reporter | 1 | 2013 | 1527 | 0.020 |
Why?
|
Genotype | 1 | 2024 | 12945 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2017 | 4839 | 0.020 |
Why?
|
Prognosis | 2 | 2021 | 29557 | 0.020 |
Why?
|
Mice, Knockout | 2 | 2015 | 14354 | 0.020 |
Why?
|
Disease Models, Animal | 2 | 2020 | 18119 | 0.020 |
Why?
|
Interleukins | 1 | 2013 | 783 | 0.020 |
Why?
|
Genome, Human | 1 | 2021 | 4416 | 0.020 |
Why?
|
Pilot Projects | 1 | 2021 | 8553 | 0.020 |
Why?
|
Massachusetts | 1 | 2021 | 8823 | 0.020 |
Why?
|
Genomics | 1 | 2023 | 5790 | 0.020 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2020 | 4353 | 0.020 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2017 | 11709 | 0.020 |
Why?
|
Anticoagulants | 1 | 2021 | 4777 | 0.020 |
Why?
|
Sequence Analysis, RNA | 1 | 2013 | 2001 | 0.020 |
Why?
|
Antibodies, Monoclonal | 1 | 2022 | 9160 | 0.020 |
Why?
|
Transplantation, Heterologous | 1 | 2014 | 2378 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2017 | 8530 | 0.020 |
Why?
|
NF-kappa B | 1 | 2013 | 2472 | 0.020 |
Why?
|
Biopsy | 1 | 2017 | 6768 | 0.020 |
Why?
|
RNA Interference | 1 | 2013 | 2836 | 0.020 |
Why?
|
Hematopoietic Stem Cells | 1 | 2017 | 3384 | 0.010 |
Why?
|
Up-Regulation | 1 | 2013 | 4113 | 0.010 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2013 | 2858 | 0.010 |
Why?
|
Genetic Vectors | 1 | 2013 | 3380 | 0.010 |
Why?
|
United States | 2 | 2021 | 72136 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2009 | 36284 | 0.010 |
Why?
|
Pandemics | 1 | 2021 | 8611 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2019 | 15785 | 0.010 |
Why?
|
Disease Progression | 1 | 2015 | 13468 | 0.010 |
Why?
|
Risk Assessment | 1 | 2017 | 23884 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2013 | 22003 | 0.010 |
Why?
|